Key result
Dual endothelin A/B receptor antagonism increases total resting energy expenditure in overweight or obese individuals.
Why the study?
Does dual endothelin A/B receptor antagonism increase resting energy expenditure in overweight/obese individuals?
Does dual endothelin A/B receptor antagonism increase resting energy expenditure in overweight/obese individuals?
Dual endothelin A/B receptor antagonism increases resting energy expenditure in overweight/obese individuals, suggesting a potential novel target for weight loss and CVD risk reduction.
May increase REE in overweight/obese adults; hypothesis-generating and requires larger trials before clinical consideration.
Findings from our current translational investigation demonstrate that dual endothelin A/B receptor antagonism increases total REE in overweight/obese individuals. These results suggest that modulation of the endothelin system may represent a novel therapeutic target to increase both resting metabolism and caloric expenditure, enhance weight loss, and reduce CVD risk in seemingly healthy individuals with elevated adiposity.
No takes yet. Share an insight, caveat, or question.
Derella et al. (2022) studied Increased adiposity (overweight/obese). Dual endothelin A/B receptor antagonism was evaluated on Total resting energy expenditure (REE). Dual endothelin A/B receptor antagonism increases total resting energy expenditure in overweight or obese individuals.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: